Martingale Asset Management’s ImmunityBio IBRX Stock Holding History

Martingale Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-21,166	Closed	-$107K	–	857
2022 Q4	$107K	Buy	21,166 +2,730	+15%	+$15K	﹤0.01%	817
2022 Q3	$92K	Buy	18,436 +5	+0%	+$23	﹤0.01%	808
2022 Q2	$69K	Buy	18,431 +6	+0%	+$24	﹤0.01%	832
2022 Q1	$104K	Buy	+18,425	New	+$113K	﹤0.01%	793
2017 Q2	–	Sell	-14,400	Closed	-$52K	–	969
2017 Q1	$52K	Sell	14,400 -4,900	-25%	-$24.2K	﹤0.01%	930
2016 Q4	$111K	Hold	19,300	–	–	﹤0.01%	951
2016 Q3	$151K	Buy	+19,300	New	+$144K	﹤0.01%	934

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Martingale Asset Management's IBRX Position: Q1 2023 in Review

Martingale Asset Management sold out of ImmunityBio (IBRX) in Q1 2023, closing a stake of 21,166 shares — an estimated $107K sold.

Martingale Asset Management first reported a position in IBRX in Q3 2016 and held it in 7 quarters. The position peaked at $151K in Q3 2016. 146 funds tracked by Wall St. Rank hold IBRX as of Q1 2023.

Martingale Asset Management reported no remaining ImmunityBio position as of Q1 2023 after selling out during the quarter.
Martingale Asset Management sold 21,166 ImmunityBio shares in Q1 2023, an estimated $107K.
Martingale Asset Management first reported a position in ImmunityBio in Q3 2016 and held it in 7 quarters.
Martingale Asset Management's ImmunityBio position peaked at $151K in Q3 2016.
146 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2023.

Based on Martingale Asset Management's 13F filing for Q1 2023, filed 12 May 2023.